Intra Cellular Therapies Stock Current Valuation
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
Valuation analysis of Intra Cellular Therapies helps investors to measure Intra Cellular's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Intra Cellular's price fluctuation is very steady at this time. Calculation of the real value of Intra Cellular Therapies is based on 3 months time horizon. Increasing Intra Cellular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Intra Cellular is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Intra Stock. However, Intra Cellular's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 131.87 | Real 101.46 | Hype 131.87 | Naive 134.87 |
The intrinsic value of Intra Cellular's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Intra Cellular's stock price.
Estimating the potential upside or downside of Intra Cellular Therapies helps investors to forecast how Intra stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Intra Cellular more accurately as focusing exclusively on Intra Cellular's fundamentals will not take into account other important factors: Intra Cellular Therapies Company Current Valuation Analysis
Intra Cellular's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Intra Cellular Current Valuation | 13.06 B |
Most of Intra Cellular's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra Cellular Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Intra Cellular Therapies has a Current Valuation of 13.06 B. This is 9.05% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 21.42% higher than that of the company.
Intra Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra Cellular's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra Cellular could also be used in its relative valuation, which is a method of valuing Intra Cellular by comparing valuation metrics of similar companies.Intra Cellular is currently under evaluation in current valuation category among its peers.
Intra Fundamentals
| Return On Equity | -0.0858 | |||
| Return On Asset | -0.0696 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.15) % | |||
| Current Valuation | 13.06 B | |||
| Shares Outstanding | 106.52 M | |||
| Shares Owned By Insiders | 2.48 % | |||
| Shares Owned By Institutions | 96.40 % | |||
| Number Of Shares Shorted | 2.67 M | |||
| Price To Earning | (6.56) X | |||
| Price To Book | 12.23 X | |||
| Price To Sales | 20.63 X | |||
| Revenue | 680.85 M | |||
| Gross Profit | 387.77 M | |||
| EBITDA | (116.72 M) | |||
| Net Income | (74.68 M) | |||
| Cash And Equivalents | 628.74 M | |||
| Cash Per Share | 6.64 X | |||
| Total Debt | 16.98 M | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 9.81 X | |||
| Book Value Per Share | 10.81 X | |||
| Cash Flow From Operations | (73.18 M) | |||
| Short Ratio | 1.20 X | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 132.0 | |||
| Number Of Employees | 860 | |||
| Beta | 0.46 | |||
| Market Capitalization | 14.05 B | |||
| Total Asset | 1.37 B | |||
| Retained Earnings | (1.69 B) | |||
| Working Capital | 1.1 B | |||
| Current Asset | 541.82 M | |||
| Current Liabilities | 140.69 M | |||
| Net Asset | 1.37 B |
About Intra Cellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intra Cellular Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra Cellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra Cellular Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets |